Free Trial
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$137.28
-10.9%		$86.86
$41.50
▼
$166.48
$6.13B2.83980,505 shs2.03 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$93.41
-1.2%		$103.03
$28.16
▼
$155.29
$1.37B3.81316,484 shs169,386 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$77.09
+1.0%		$77.56
$35.20
▼
$82.94
$6.01B0.04682,428 shs378,742 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$42.45
-2.2%		$52.14
$27.07
▼
$61.76
$5.17B0.611.43 million shs1.86 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+7.55%+16.17%+91.78%+123.99%+135.09%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-2.51%-7.03%-21.96%-6.14%+165.25%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+0.69%+0.28%-2.05%+13.40%+98.26%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-7.28%-11.66%-21.56%-23.27%+15.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$137.28
-10.9%		$86.86
$41.50
▼
$166.48
$6.13B2.83980,505 shs2.03 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$93.41
-1.2%		$103.03
$28.16
▼
$155.29
$1.37B3.81316,484 shs169,386 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$77.09
+1.0%		$77.56
$35.20
▼
$82.94
$6.01B0.04682,428 shs378,742 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$42.45
-2.2%		$52.14
$27.07
▼
$61.76
$5.17B0.611.43 million shs1.86 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+7.55%+16.17%+91.78%+123.99%+135.09%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-2.51%-7.03%-21.96%-6.14%+165.25%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+0.69%+0.28%-2.05%+13.40%+98.26%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-7.28%-11.66%-21.56%-23.27%+15.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$102.70-25.19% Downside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.50
Moderate Buy$197.50111.43% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.78
Moderate Buy$93.1420.82% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
2.94
Moderate Buy$66.7557.24% Upside

Current Analyst Ratings Breakdown

Latest INBX, SRRK, KNSA, and GRAL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$105.00 ➝ $175.00
10/1/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $155.00
9/30/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$87.00
9/28/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $150.00
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$65.00 ➝ $100.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$76.00 ➝ $77.00
9/22/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $118.00
9/21/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$70.00
9/21/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$63.00 ➝ $70.00
9/18/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRAIL, Inc. stock logo
GRAL
GRAIL
$165.26M37.10N/AN/A$66.13 per share2.08
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/A$0.55 per shareN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$840.85M7.15$0.81 per share95.48$7.44 per share10.36
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$8.88N/AN/AN/AN/A-563.90%-83.48%11/13/2026 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$0.9779.4737.24N/A9.59%13.65%10.09%10/27/2026 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.45N/AN/AN/AN/A-160.19%-87.18%11/13/2026 (Estimated)

Latest INBX, SRRK, KNSA, and GRAL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.3699N/AN/AN/A$259.65 millionN/A
8/13/2026Q2 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.28-$2.34-$0.06-$2.34N/AN/A
8/6/2026Q2 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8405-$0.84+$0.0005-$0.84$3.33 millionN/A
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
7/28/2026Q2 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.2995$0.30+$0.0005$0.30$226.49 million$243.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/A
5.07
5.07
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.90
3.49
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.77
7.02
7.02

Institutional Ownership

CompanyInstitutional Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
53.95%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
18.26%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
51.98%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
11014.72 million12.03 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
36678.02 million37.47 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
289121.79 million109.24 millionOptionable

Recent News About These Companies

Scholar Rock (NASDAQ:SRRK) Shares Down 5.1% - Here's Why
October 5 at 1:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scholar-rock-nasdaq-srrk-shares-down-51-heres-why-2026-10-05/
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-scholar-rock-holding-corp-to-contact-law-firm-302893822.html
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-decision-watch-bmy-egtx-104443345.html
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
September 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-poised-risked-commercial-163551479.html
How Scholar Rock Holding Corporation (SRRK) Affects Rotational Strategy Timing
September 23, 2026  |  news.stocktradersdaily.comN
Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scholar-rock-nasdaq-srrk-shares-up-6-following-analyst-upgrade-2026-09-22/
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 21, 2026
September 22, 2026  |  biospace.comB
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-scholar-rock-nasdaq-srrk-stock-price-expected-to-rise-jpmorgan-chase-co-analyst-says-2026-09-21/
Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-takes-5347-million-position-in-scholar-rock-holding-corporation-srrk-2026-09-21/
Scholar Rock Holding (SRRK) Receives a Buy from Piper Sandler
September 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SRRK/pressreleases/4628246/scholar-rock-holding-srrk-receives-a-buy-from-piper-sandler/
Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-scholar-rock-nasdaq-srrk-raised-to-strong-buy-at-jefferies-financial-group-2026-09-17/
HC Wainwright Lowers Earnings Estimates for Scholar Rock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-lowers-earnings-estimates-for-scholar-rock-2026-09-17/
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
September 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/scholar-rock-holding-srrk-wins-fda-approval-for-isembyld-can-add-on-use-scale-1837453/
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/scholar-rock-srrk-stock-fair-231604235.html
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-faces-early-isembyld-185203987.html
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946665-scholar-rock-strong-buy-on-fda-approval-sma-and-expansions-now-in-play
Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/scholar-rock-downgraded-at-barclays-despite-fda-approval-of-sma-therapy/ar-AA2ch10y
Scholar Rock (NASDAQ:SRRK) Shares Down 7.1% - Here's What Happened
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scholar-rock-nasdaq-srrk-shares-down-71-heres-what-happened-2026-09-15/
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
September 15, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/downgrades/26/09/61791446/this-cellectis-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday?utm_source=snapi
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/srrk-shares-pull-back-fda-203015507.html
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946041-scholar-rock-holding-corporation-srrk-discusses-fda-approval-and-clinical-impact-of-isembyld

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Stacks of US currency and an official document sit on a desk in a government chamber.
3 Stocks to Buy and Hold for Higher Interest Rates
By Thomas Hughes | September 9, 2026
Inhibrx logo overlaid on a laboratory scene with vials, pipettes, and a computer screen showing a protein model.
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
By Jeffrey Neal Johnson | October 2, 2026
GRAIL stock logo

GRAIL NASDAQ:GRAL

$137.28 -16.80 (-10.90%)
Closing price 04:00 PM Eastern
Extended Trading
$137.98 +0.70 (+0.51%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$93.41 -1.15 (-1.22%)
Closing price 04:00 PM Eastern
Extended Trading
$93.50 +0.09 (+0.09%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$77.09 +0.78 (+1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$78.68 +1.59 (+2.06%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$42.45 -0.95 (-2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$42.40 -0.05 (-0.13%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas